Small molecule · developed by Serina Therapeutics
SER-252 is a lyophilized formulation containing apomorphine, supplied as a sterile vial for reconstitution with an acetate-buffered, trehalose-containing diluent. It is being studied in advanced Parkinson's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07422675 | Phase 1 | PARKINSON DISEASE (Disorder) | Recruiting | SER |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Parkinson's DiseasePARKINSON DISEASE (Disorder)
Updated Nov 1, 2026. Something wrong or missing? Report it on the SER page.
See SER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SER catalysts and pipeline →